FAM230J

Across TCGA pan-cancer cohorts, FAM230J Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM230J data layer compared with 8 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher FAM230J Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM230J expression acts as an unfavorable survival marker.

CESC, ESCA, and OV are the cancer types where FAM230J Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.140	0.823	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.381	0.711	.013	12	view →
OV	DFS	Median	All	0.132	0.541	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM230J–CESC (DFS)

Open the CESC breakdown →